The Prognostic Value of 2-Deoxy-2-[18F]Fluoro-D-Glucose Positron Emission Tomography in Patients With Suspected Residual or Recurrent Medullary Thyroid Carcinoma

被引：28

作者：

Bogsrud, Trond Velde ^{[2
]}

Karantanis, Dimitrios ^{[1
]}

Nathan, Mark A. ^{[1
]}

Mullan, Brian P. ^{[1
]}

Wiseman, Gregory A. ^{[1
]}

Kasperbauer, Jan L. ^{[3
]}

Reading, Carl C. ^{[4
]}

Bjoro, Trine ^{[5
]}

Hay, Ian D. ^{[6
]}

Lowe, Val J. ^{[1
]}

机构：

[1] Mayo Clin, Dept Radiol, Div Nucl Med, Rochester, MN 55905 USA

[2] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Radiol, Div Nucl Med, Oslo, Norway

[3] Mayo Clin, Dept Otorhinolaryngol, Rochester, MN 55905 USA

[4] Mayo Clin, Dept Radiol, Div Ultrasonog, Rochester, MN 55905 USA

[5] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Clin Biochem, Oslo, Norway

[6] Mayo Clin, Dept Internal Med, Div Endocrinol, Rochester, MN 55905 USA

来源：

MOLECULAR IMAGING AND BIOLOGY | 2010年 / 12卷 / 05期

关键词：

2-deoxy-2-[18F]fluoro-D-glucose; FDG; Medullary thyroid carcinoma; PET; PET/CT; Positron emission tomography; ELEVATED CALCITONIN LEVELS; ANTIGEN DOUBLING-TIMES; BIOCHEMICAL-EVIDENCE; F-18-FDG PET; CANCER; IMPACT; SURVIVAL;

D O I：

10.1007/s11307-009-0276-2

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

To explore the prognostic value of 2-deoxy-2-[18F]fluoro-d-glucose (FDG) positron emission tomography (PET) in patients with suspected residual or recurrent medullary thyroid carcinoma (MTC). This retrospective study included all patients with MTC examined with FDG-PET at Mayo Clinic, Rochester, Minnesota, from October 1999 to March 2008. The PET results were compared with other imaging studies and clinical findings, including carcinoembryonic antigen and calcitonin levels. Twenty-nine patients with MTC were included. PET was positive in 14 patients, with follow-up information for 11; six died from metastatic disease, four had disease progression, and one remained in stable condition. PET was negative in 15 patients, with follow-up for 12; one had recurrent disease, and 11 had no evidence of clinical disease. Calcitonin doubling time was shorter for PET-positive than for PET-negative patients. FDG-PET has high prognostic value in patients with suspected residual or recurrent MTC.

引用

页码：547 / 553

页数：7

共 27 条

[21] Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging [J].

Pellegriti, G ;

Leboulleux, S ;

Baudin, E ;

Bellon, N ;

Scollo, C ;

Travagli, JP ;

Schlumberger, M .

BRITISH JOURNAL OF CANCER, 2003, 88 (10) :1537-1542

[22] Clinical applications of PET in oncology [J].

Rohren, EM ;

Turkington, TG ;

Coleman, RE .

RADIOLOGY, 2004, 231 (02) :305-332

[23] Prognosis of medullary thyroid carcinoma - Demographic, clinical, and pathologic predictors of survival in 1252 cases [J].

Roman, Sanziana ;

Lin, Rong ;

Sosa, Julie Ann .

CANCER, 2006, 107 (09) :2134-2142

[24]

SCHLUMBERGER M, 2003, THYROID TUMORS, P305

[25]

Szakáll Z, 2002, J NUCL MED, V43, P66

[26] Medullary thyroid carcinoma: Results of a standardized surgical approach in a contemporary series of 80 consecutive patients [J].

Yen, TWF ;

Shapiro, SE ;

Gagel, RF ;

Sherman, SI ;

Lee, JE ;

Evans, DB .

SURGERY, 2003, 134 (06) :890-899

[27] Medullary thyroid cancer [J].

You, Y. Nancy ;

Lakhani, Vipul ;

Wells, Samuel A., Jr. ;

Moley, Jeffrey F. .

SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2006, 15 (03) :639-+

← 1 2 3 →